Patent · US Active

Antibodies directed to HER-3 and uses thereof

US8771695B2 · kind B2 · utility

7Cited by

42References

20Claims

0Family size

Assignees

U3 Pharma GmbH · DE
AMGEN INC. · US

Inventors

Mike Rothe · San Mateo, US
Martin Treder · Heidelberg, DE
Susanne Hartmann · Munich, DE
Daniel J. Freeman · Newbury Park, US
Robert Radinsky · Thousand Oaks, US
Eric Borges · Weitensfeld im Gurktal, AT

Key dates

Filing date	Apr 15, 2010
Grant date	Jul 8, 2014
Priority date	—
Expiry date	Apr 26, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2800/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.